Deferiprone
Overview
Deferiprone is an oral iron chelator used to treat iron overload in patients with transfusion-dependent thalassemia. It forms a stable complex with trivalent iron (Fe3+) and is then eliminated from the body, reducing iron levels and preventing organ damage.
API suppliers (7)
Suppliers of Deferiprone evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
4 of 7 hold a GMP certificate on record in the EU or UK registers · 1 holds a European CEP for this substance
- AARTI PHARMALABS LIMITEDIndia1 active DMF
- Emcure Pharmaceuticals LimitedIndia1 active DMF GMP on record
- Taro Pharmaceutical Industries Ltd.Israel1 active DMF GMP on record
- INDUSTRIALE CHIMICA SRLItaly1 active DMF GMP on record
- Apotex Inc.Canada1 active DMF
- KATWIJK CHEMIE BVNetherlandsCEP GMP on record
- Cadila Healthcare LimitedIndia
Patent & exclusivity (US)
Per the FDA Orange Book (9 approved US products), the latest listed US patent on Deferiprone expires 25 Oct 2038 and exclusivity 30 Apr 2028. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Deferiprone? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.